%0 Journal Article
%T Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.
%A Mooghali M
%A Mohammad A
%A Wallach JD
%A Mitchell AP
%A Ross JS
%A Ramachandran R
%J JAMA Netw Open
%V 7
%N 5
%D 2024 May 1
%M 38691363
%F 13.353
%R 10.1001/jamanetworkopen.2024.9233
%X This cross-sectional study evaluates the use of the US Food and Drug Administration’s Real-Time Oncology Review (RTOR) program in confirming the effectiveness of cancer drugs.